BiotechTube

Gemcitabine + liposomal doxorubicin

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Genital Neoplasms, Female

Conditions

Genital Neoplasms, Female, Fallopian Tube Neoplasms, Ovarian Neoplasms, Pelvic Neoplasms, Peritoneal Neoplasms

Trial Timeline

Jul 1, 2002 → Nov 1, 2005

NCT ID
NCT00191607

About Gemcitabine + liposomal doxorubicin

Gemcitabine + liposomal doxorubicin is a phase 3 stage product being developed by Eli Lilly for Genital Neoplasms, Female. The current trial status is completed. This product is registered under clinical trial identifier NCT00191607. Target conditions include Genital Neoplasms, Female, Fallopian Tube Neoplasms, Ovarian Neoplasms.

What happened to similar drugs?

10 of 20 similar drugs in Genital Neoplasms, Female were approved

Approved (10) Terminated (0) Active (10)
✅Risankizumab + Placebo for RisankizumabAbbVieApproved
✅Famciclovir + PlaceboNovartisApproved
✅FamciclovirNovartisApproved
✅FamciclovirNovartisApproved
✅turoctocog alfaNovo NordiskApproved
✅eptacog alfa (activated) + Feiba VHNovo NordiskApproved
✅activated recombinant human factor VIINovo NordiskApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00191607Phase 3Completed

Competing Products

20 competing products in Genital Neoplasms, Female

See all competitors
ProductCompanyStageHype Score
mRNA-1608ModernaPhase 2
0
TideglusibAMO PharmaPre-clinical
20
Tideglusib + PlaceboAMO PharmaPhase 2/3
28
TideglusibAMO PharmaPhase 2/3
35
Fulvestrant + AbemaciclibEli LillyPhase 2
39
EDIT-101Editas MedicinePhase 1/2
18
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
17
SPR001Spruce BiosciencesPhase 2
25
SPR001Spruce BiosciencesPhase 2
25
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
17
TildacerfontSpruce BiosciencesPhase 2
17
ASP2151 + PlaceboAstellas PharmaPhase 1
29
ASP2151 + valacyclovir + PlaceboAstellas PharmaPhase 2
35
Tildrakizumab 100 mg + PlaceboSun PharmaceuticalPhase 3
44
Topical NO + PlaceboKyowa KirinPhase 2
35
KW-3357Kyowa KirinPhase 1
29
Ixekizumab + PlaceboEli LillyPhase 3
40
Gemcitabine + Paclitaxel + CarboplatinEli LillyPhase 3
40
DaratumumabJohnson & JohnsonPhase 2
27
Risankizumab + Placebo for RisankizumabAbbVieApproved
43